InsiderDirector

Noubar Afeyan Insider Trading Activity

Every SEC Form 4 transaction reported by Noubar Afeyan, sourced directly from SEC EDGAR and updated as new filings are accepted.

Latest filing:

Compiled automatically from SEC EDGAR Form 4 filings and refreshed daily. Figures count purchases (code P) and sales (code S) only — not grants, option exercises, or gifts. How this page is built. Not investment advice.

Quick Answer

Is Noubar Afeyan buying or selling?

Noubar Afeyan reported 3 open-market buys ($170.0M) and 86 sells ($1.6B) across 89 Form 4 filings at 3 companies — a net selling position of $1.5B.

Source: SEC EDGAR Form 4

What stands out

  • Noubar Afeyan has reported Form 4 transactions at 3 companies; the most active, Moderna, Inc. (MRNA), accounts for 86 of 89 filings (97%).
  • The most recent Form 4 was accepted on May 22, 2026 (4 months ago).
  • In the last 12 months: 2 open-market purchases ($150.0M) and 2 sales ($1.1M).
  • The largest open-market purchase in the last 12 months was $75.0M of Generate Biomedicines, Inc. (GENB) on Mar 2, 2026. SEC ↗

Key Statistics (as of May 22, 2026)

Total Form 4 filings
89
SEC EDGAR
Companies
3
Buys (3)
$170.0M
Sells (86)
$1.6B

Insider sentiment

Net selling

Net insider flow of $1.5B in net selling, filed between Jun 20, 2019 – May 22, 2026.

Companies Noubar Afeyan files for

#CompanyForm 4 filings
1MRNAModerna, Inc.86
2GENBGenerate Biomedicines, Inc.2
3MCRBSeres Therapeutics, Inc.1

Recent Noubar Afeyan transactions

DateTickerRoleTypeSharesValueFiling
May 22, 2026MRNADirectorSale9.3K$433.9KSEC ↗
Mar 2, 2026GENBDirector, 10% OwnerPurchase4.7M$75.0MSEC ↗
Mar 2, 2026GENBDirector, 10% OwnerPurchase4.7M$75.0MSEC ↗
Dec 15, 2025MRNADirectorSale23.9K$703.3KSEC ↗
Aug 2, 2024MRNADirectorSale15.0K$1.8MSEC ↗
Jul 26, 2024MRNADirectorSale15.0K$1.8MSEC ↗
Jul 19, 2024MRNADirectorSale15.0K$1.8MSEC ↗
Jul 12, 2024MRNADirectorSale15.0K$1.8MSEC ↗
Jun 28, 2024MRNADirectorSale15.0K$1.9MSEC ↗
Jun 21, 2024MRNADirectorSale15.0K$2.0MSEC ↗
Jun 14, 2024MRNADirectorSale15.0K$2.2MSEC ↗
Jun 11, 2024MRNADirectorSale202.8K$30.1MSEC ↗
Jun 7, 2024MRNADirectorSale15.0K$2.3MSEC ↗
May 31, 2024MRNADirectorSale20.0K$2.9MSEC ↗
May 24, 2024MRNADirectorSale15.0K$2.4MSEC ↗
May 17, 2024MRNADirectorSale15.0K$1.9MSEC ↗
May 10, 2024MRNADirectorSale15.0K$1.8MSEC ↗
May 3, 2024MRNADirectorSale15.0K$1.7MSEC ↗
Apr 26, 2024MRNADirectorSale15.0K$1.6MSEC ↗
Apr 19, 2024MRNADirectorSale15.0K$1.6MSEC ↗
Apr 12, 2024MRNADirectorSale15.0K$1.6MSEC ↗
Apr 5, 2024MRNADirectorSale15.0K$1.5MSEC ↗
Mar 29, 2024MRNADirectorSale15.0K$1.6MSEC ↗
Mar 22, 2024MRNADirectorSale15.0K$1.5MSEC ↗
Mar 15, 2024MRNADirectorSale15.0K$1.6MSEC ↗

Showing the 25 most recent filings of 89. Screen every filing.

Noubar Afeyan insider trading FAQ

Is Noubar Afeyan buying or selling?

Across 89 SEC Form 4 filings, Noubar Afeyan reported 3 open-market purchases totaling $170.0M and 86 sales totaling $1.6B — a net selling position of $1.5B.

Which companies does Noubar Afeyan file Form 4s for?

Noubar Afeyan has reported insider transactions at 3 companies, most often Moderna, Inc. (MRNA), Generate Biomedicines, Inc. (GENB), Seres Therapeutics, Inc. (MCRB).

How far back does Noubar Afeyan's filing history go?

Trabud holds Noubar Afeyan's SEC Form 4 filings from Jun 20, 2019 – May 22, 2026, sourced directly from SEC EDGAR.

Where does Trabud get Noubar Afeyan's insider trading data?

Directly from SEC EDGAR Form 4 filings. Every transaction on this page is a real filing accepted by the SEC, updated as new filings arrive.

Related Content

Track Noubar Afeyan and every other insider

Screen all SEC Form 4 filings by insider, company, transaction value, and role — or ask Trabud's AI agent in plain English.

Open the screener